DK4076662T3 - Pyrazolylderivativer der er nyttige som anti-cancermidler - Google Patents
Pyrazolylderivativer der er nyttige som anti-cancermidler Download PDFInfo
- Publication number
- DK4076662T3 DK4076662T3 DK20829365.4T DK20829365T DK4076662T3 DK 4076662 T3 DK4076662 T3 DK 4076662T3 DK 20829365 T DK20829365 T DK 20829365T DK 4076662 T3 DK4076662 T3 DK 4076662T3
- Authority
- DK
- Denmark
- Prior art keywords
- cancer agents
- derivatives useful
- pyrazolyl derivatives
- pyrazolyl
- useful
- Prior art date
Links
- -1 PYRAZOLYL Chemical class 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962951400P | 2019-12-20 | 2019-12-20 | |
| PCT/CN2020/125425 WO2021120890A1 (en) | 2019-12-20 | 2020-10-30 | Pyrazolyl derivatives useful as anti-cancer agents |
| PCT/IB2020/062144 WO2021124222A1 (en) | 2019-12-20 | 2020-12-17 | Pyrazolyl derivatives useful as anti-cancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4076662T3 true DK4076662T3 (da) | 2024-04-22 |
Family
ID=76477081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20829365.4T DK4076662T3 (da) | 2019-12-20 | 2020-12-17 | Pyrazolylderivativer der er nyttige som anti-cancermidler |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11702409B2 (da) |
| EP (2) | EP4344702A3 (da) |
| JP (2) | JP2023506841A (da) |
| KR (1) | KR20220114064A (da) |
| CN (1) | CN114929342A (da) |
| AR (1) | AR120855A1 (da) |
| AU (1) | AU2020410531B2 (da) |
| CA (1) | CA3165148A1 (da) |
| CL (1) | CL2022001625A1 (da) |
| CO (1) | CO2022008344A2 (da) |
| CR (1) | CR20220281A (da) |
| DK (1) | DK4076662T3 (da) |
| DO (1) | DOP2022000124A (da) |
| EC (1) | ECSP22047876A (da) |
| FI (1) | FI4076662T3 (da) |
| IL (1) | IL293893A (da) |
| JO (1) | JOP20220155A1 (da) |
| MX (1) | MX2022007350A (da) |
| PE (1) | PE20221910A1 (da) |
| PT (1) | PT4076662T (da) |
| TW (1) | TW202136241A (da) |
| UY (1) | UY38990A (da) |
| WO (2) | WO2021120890A1 (da) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20220230A (es) | 2019-10-28 | 2022-06-15 | Merck Sharp & Dohme | Inhibidores de pequeñas moléculas de mutante g12c de kras |
| US20230212164A1 (en) | 2020-06-02 | 2023-07-06 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
| TW202227460A (zh) | 2020-09-15 | 2022-07-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| US20240116900A1 (en) * | 2020-10-30 | 2024-04-11 | Novartis Ag | New crystalline forms of a kras g12c inhibitor compound |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| WO2022133731A1 (en) * | 2020-12-22 | 2022-06-30 | Novartis Ag | Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor and for the treatment of cancers |
| CN116710094A (zh) * | 2020-12-22 | 2023-09-05 | 诺华股份有限公司 | 包含kras g12c抑制剂的药物组合以及kras g12c抑制剂用于治疗癌症的用途 |
| AR125782A1 (es) | 2021-05-05 | 2023-08-16 | Revolution Medicines Inc | Inhibidores de ras |
| US20220396589A1 (en) | 2021-05-05 | 2022-12-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2022246459A1 (en) * | 2021-05-19 | 2022-11-24 | Genentech, Inc. | Combination therapy |
| CN117425649A (zh) * | 2021-06-23 | 2024-01-19 | 诺华股份有限公司 | 作为kras突变蛋白抑制剂的吡唑衍生物 |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| CN117677398A (zh) | 2021-07-27 | 2024-03-08 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| WO2023031781A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| TW202332429A (zh) | 2021-11-24 | 2023-08-16 | 美商建南德克公司 | 治療性化合物及其使用方法 |
| WO2023097194A2 (en) | 2021-11-24 | 2023-06-01 | Genentech, Inc. | Therapeutic compounds and methods of use |
| WO2023099592A1 (en) * | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023122662A1 (en) | 2021-12-22 | 2023-06-29 | The Regents Of The University Of California | Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase |
| TW202332434A (zh) * | 2022-01-31 | 2023-08-16 | 瑞士商諾華公司 | 可用作抗癌劑的吡唑基衍生物之合成方法 |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023199180A1 (en) | 2022-04-11 | 2023-10-19 | Novartis Ag | Therapeutic uses of a krasg12c inhibitor |
| WO2023230205A1 (en) | 2022-05-25 | 2023-11-30 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024040131A1 (en) | 2022-08-17 | 2024-02-22 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| CN116478141B (zh) * | 2023-06-20 | 2023-10-24 | 药康众拓(江苏)医药科技有限公司 | 氘代kras抑制剂药物及用途 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1199600A (en) * | 1998-10-02 | 2000-04-26 | Board Of Trustees Of The University Of Illinois, The | Estrogen receptor ligands |
| CL2004000234A1 (es) | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
| JP2008511630A (ja) | 2004-08-31 | 2008-04-17 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | ＴＧＦ−βインヒビターとしてのピリミジニルピラゾール |
| TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| WO2007002563A1 (en) * | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Imidazole based lxr modulators |
| EP2024353A2 (en) * | 2006-03-16 | 2009-02-18 | Pfizer Products Inc. | Pyrazole compounds |
| EP2170337A4 (en) | 2007-06-28 | 2013-12-18 | Abbvie Inc | NEW TRIAZOLOPYRIDAZINE |
| US7897619B2 (en) * | 2007-07-17 | 2011-03-01 | Amgen Inc. | Heterocyclic modulators of PKB |
| WO2009016460A2 (en) | 2007-08-01 | 2009-02-05 | Pfizer Inc. | Pyrazole compounds and their use as raf inhibitors |
| PL2324008T3 (pl) * | 2008-07-24 | 2012-09-28 | Nerviano Medical Sciences Srl | 3,4-diarylopirazole jako inhibitory kinazy białkowej |
| WO2010108268A1 (en) * | 2009-03-23 | 2010-09-30 | Merck Frosst Canada Ltd. | Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| EP2601185B1 (en) * | 2010-08-03 | 2015-10-07 | Nerviano Medical Sciences S.r.l. | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents |
| EP2836482B1 (en) | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
| EP2970121B1 (en) | 2013-03-15 | 2017-12-13 | Araxes Pharma LLC | Covalent inhibitors of kras g12c |
| KR20160076519A (ko) | 2013-10-10 | 2016-06-30 | 아락세스 파마 엘엘씨 | Kras g12c 억제제 |
| EA201792214A1 (ru) | 2015-04-10 | 2018-01-31 | Араксис Фарма Ллк | Соединения замещенного хиназолина |
| WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017201161A1 (en) | 2016-05-18 | 2017-11-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| CN108069955B (zh) | 2016-11-14 | 2021-04-06 | 江苏恒瑞医药股份有限公司 | 3-吡啶基-4-苯并噻唑基吡唑类衍生物、其制备方法及其在医药上的应用 |
| MX2019004822A (es) | 2016-11-14 | 2019-09-11 | Jiangsu Hengrui Medicine Co | Derivado del pirazol 3,4-bipiridilo y metodo de preparacion del mismo y aplicacion medica del mismo. |
| MX2019007643A (es) | 2016-12-22 | 2019-09-09 | Amgen Inc | Benzoisotiazol, isotiazolo[3,4-b]piridina, quinazolina, ftalazina, pirido[2,3-d]piridazina y derivados de pirido[2,3-d]pirimidina como inhibirores de kras g12c para tratar el cancer de pulmon, pancreatico o colorrectal. |
| EP3573970A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| US20200385364A1 (en) | 2017-01-26 | 2020-12-10 | Araxes Pharma Llc | Fused n-heterocyclic compounds and methods of use thereof |
| US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
| EP3573967A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| JOP20190186A1 (ar) | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| US10745385B2 (en) | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| SI3710439T1 (sl) | 2017-11-15 | 2023-06-30 | Mirati Therapeutics, Inc., | Zaviralci mutacije kras g12c |
| WO2019136147A1 (en) * | 2018-01-03 | 2019-07-11 | The Board Of Trustees Of The University Of Illinois | Toll-like receptor signaling inhibitors |
| PE20211447A1 (es) * | 2018-02-23 | 2021-08-05 | Samumed Llc | Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparacion y uso de las mismas |
| US11090304B2 (en) * | 2018-05-04 | 2021-08-17 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| JP7361720B2 (ja) | 2018-05-10 | 2023-10-16 | アムジエン・インコーポレーテツド | がんの治療のためのｋｒａｓ ｇ１２ｃ阻害剤 |
| MX2020012731A (es) | 2018-06-01 | 2021-02-22 | Amgen Inc | Inhibidores de kras g12c y metodos para su uso. |
-
2020
- 2020-10-30 WO PCT/CN2020/125425 patent/WO2021120890A1/en not_active Application Discontinuation
- 2020-12-17 CN CN202080089867.2A patent/CN114929342A/zh active Pending
- 2020-12-17 DK DK20829365.4T patent/DK4076662T3/da active
- 2020-12-17 PE PE2022001123A patent/PE20221910A1/es unknown
- 2020-12-17 IL IL293893A patent/IL293893A/en unknown
- 2020-12-17 US US17/125,335 patent/US11702409B2/en active Active
- 2020-12-17 JP JP2022536692A patent/JP2023506841A/ja active Pending
- 2020-12-17 KR KR1020227024285A patent/KR20220114064A/ko unknown
- 2020-12-17 UY UY0001038990A patent/UY38990A/es unknown
- 2020-12-17 AU AU2020410531A patent/AU2020410531B2/en active Active
- 2020-12-17 EP EP24151713.5A patent/EP4344702A3/en active Pending
- 2020-12-17 CA CA3165148A patent/CA3165148A1/en active Pending
- 2020-12-17 JO JOP/2022/0155A patent/JOP20220155A1/ar unknown
- 2020-12-17 MX MX2022007350A patent/MX2022007350A/es unknown
- 2020-12-17 PT PT208293654T patent/PT4076662T/pt unknown
- 2020-12-17 CR CR20220281A patent/CR20220281A/es unknown
- 2020-12-17 FI FIEP20829365.4T patent/FI4076662T3/fi active
- 2020-12-17 WO PCT/IB2020/062144 patent/WO2021124222A1/en active Application Filing
- 2020-12-17 EP EP20829365.4A patent/EP4076662B1/en active Active
- 2020-12-18 TW TW109145169A patent/TW202136241A/zh unknown
- 2020-12-21 AR ARP200103593A patent/AR120855A1/es unknown
-
2022
- 2022-06-15 CO CONC2022/0008344A patent/CO2022008344A2/es unknown
- 2022-06-15 DO DO2022000124A patent/DOP2022000124A/es unknown
- 2022-06-15 CL CL2022001625A patent/CL2022001625A1/es unknown
- 2022-06-15 EC ECSENADI202247876A patent/ECSP22047876A/es unknown
-
2024
- 2024-01-22 JP JP2024007468A patent/JP2024056707A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FI4076662T3 (fi) | 2024-04-24 |
| PT4076662T (pt) | 2024-04-18 |
| PE20221910A1 (es) | 2022-12-23 |
| IL293893A (en) | 2022-08-01 |
| US11702409B2 (en) | 2023-07-18 |
| JP2023506841A (ja) | 2023-02-20 |
| DOP2022000124A (es) | 2022-07-31 |
| US20220363670A1 (en) | 2022-11-17 |
| JOP20220155A1 (ar) | 2023-01-30 |
| CL2022001625A1 (es) | 2023-03-24 |
| ECSP22047876A (es) | 2022-07-29 |
| WO2021120890A1 (en) | 2021-06-24 |
| AR120855A1 (es) | 2022-03-23 |
| MX2022007350A (es) | 2022-07-19 |
| TW202136241A (zh) | 2021-10-01 |
| EP4344702A2 (en) | 2024-04-03 |
| EP4076662A1 (en) | 2022-10-26 |
| KR20220114064A (ko) | 2022-08-17 |
| CN114929342A (zh) | 2022-08-19 |
| AU2020410531B2 (en) | 2024-03-07 |
| AU2020410531A1 (en) | 2022-07-28 |
| CA3165148A1 (en) | 2021-06-24 |
| EP4344702A3 (en) | 2024-04-10 |
| CO2022008344A2 (es) | 2022-06-30 |
| UY38990A (es) | 2021-07-30 |
| JP2024056707A (ja) | 2024-04-23 |
| EP4076662B1 (en) | 2024-01-31 |
| CR20220281A (es) | 2022-07-01 |
| WO2021124222A1 (en) | 2021-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4076662T3 (da) | Pyrazolylderivativer der er nyttige som anti-cancermidler | |
| DK3853220T3 (da) | Quinazolinderivater som antitumormidler | |
| DK3774791T3 (da) | Heterocykliske forbindelser som immunmodulatorer | |
| DK3558990T3 (da) | Tetrahydroimidazo[4,5-c]pyridinderivater som pd-l1 internaliseringsinducere | |
| DK3464271T3 (da) | Pyrazolderivater som plasma-kallikreininhibitorer | |
| DK3464249T3 (da) | Substituerede carbonnukleosidderivater, der er anvendelige som anticancermidler | |
| DK3768674T3 (da) | Aminopyrimidinderivater som ctps1-hæmmere | |
| DK3313838T3 (da) | Polycykliske amidderivater som cdk9-inhibitorer | |
| DK3582780T3 (da) | Aminopyrimidinforbindelser, der er anvendelige som SSAO-inhibitorer | |
| BR112017015514A2 (pt) | derivados policíclicos ativos com substituintes contendo enxofre ativos em termos pesticidas | |
| DK3322701T3 (da) | Ethynylderivater som metabotropiske glutamatreceptormodulatorer | |
| MA40774A (fr) | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 | |
| DK3464309T3 (da) | Phosphoramidatnukleosidderivater som anticancermidler | |
| DK3533796T3 (da) | Aminopyrazolopyrimidinforbindelse anvendt som neutrof faktor tyrosinkinasereceptor inhibitor | |
| DK3472165T3 (da) | N-(substituererede-phenyl)-sulfonamidderivater som kinasehæmmere | |
| BR112017028600A2 (pt) | derivados policíclicos ativos com substituintes contendo enxofre ativos em termos pesticidas | |
| DK3625222T3 (da) | Phenylderivater som pge2-receptormodulatorer | |
| BR112018000052A2 (pt) | derivados policíclicos ativos em termos pesticidas com substituintes contendo enxofre | |
| DK3544981T3 (da) | Benzodiazoliumforbindelser som enac-inhibitorer | |
| DK3625228T3 (da) | Pyrimidinderivater som pge2-receptormodulatorer | |
| DK3762368T3 (da) | Aminopyrazindiolforbindelser som pi3k-y-inhibitorer | |
| DK3672951T3 (da) | Quinoxalinderivater som adenosinreceptorantagonister | |
| DK3153508T3 (da) | Naphthofuranderivater til anvendelse som anticancermidler | |
| IL259214B (en) | Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group ii metabotropic glutamate receptors | |
| DK3768669T3 (da) | Piperazinazaspiroderivater |